Clinical Trial Update: Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants [Phase 2]

View source ↗

Summary

Phase 2 trial assessing TAK-954 effects on GI and colonic transit in diabetic and idiopathic gastroparesis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Gastroparesis
• Idiopathic Gastroparesis

Drugs mentioned

• TAK-954

Snippet

Sponsor: Takeda | Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis | Phase 2 | Status: COMPLETED | Results posted: 2020-07-15